Getinge publishes Annual Report for 2025

Getinge released its 2025 Annual Report and Sustainability statement, reporting net sales of SEK 35 billion. The year was marked by geopolitical friction and notable cost headwinds from tariffs and currency moves, but the company delivered strong underlying profitability, continued regulatory progress, and an ambitious innovation agenda.

Analysis

Medtechs with large installed bases and high consumables/services attachment rates will be the implicit winners from the current tariff/FX shock because consumables pricing can be re‑priced or re‑allocated faster than capital equipment cycles. Expect a 2–4 quarter lag where service revenue grows faster than capital sales, translating into 150–350bps of margin relief if companies re‑price and accelerate SKU rationalization aggressively.

Second-order supply chain effects: contract manufacturers in lower‑cost EU/Eastern Europe locations will see order wins from firms looking to re‑shore production out of tariff‑exposed corridors; logistics capacity will be the choke point — extended lead times of 6–10 weeks can force hospitals to overstock, temporarily boosting working capital and gross margins for suppliers who can deliver. Currency moves magnify this — a sustained SEK weakness versus EUR/USD creates a two-way P&L effect (translation losses vs local cost competitiveness) and makes hedging and local pricing strategy the decisive execution lever over the next 3–12 months.

Tail risks skew toward policy (tariff escalation or targeted sanctions) and regulatory delays on key product approvals; these are binary and can swing EBITDA by several hundred basis points within 30–180 days. The consensus underestimates the speed at which pricing and supply‑chain reconfiguration can offset headline cost hits; however, execution risk is real — companies promising aggressive innovation agendas will only convert value if they avoid multi‑quarter regulatory stalls and maintain installed base service uptime.

Key Decisions for Investors

• Long Getinge (GETI-B.ST) — buy with a 6–12 month horizon: position size 2–3% of risk budget. Rationale: expectation of >20% IRR if company converts service/pricing actions and regulatory progress continues; downside ~15–20% if tariffs/FX persist and execution slips. Put hedge: buy 6–9 month puts to cap downside at ~10–12% of notional cost.
• Pair trade — long STERIS (STE) / short Zimmer Biomet (ZBH), 6–9 months: go 1.2:1 size on STE:ZBH. Rationale: STE benefits from sterilization/consumables re‑pricing and recurring revenue resilience; ZBH more exposed to elective surgery capex cyclicality. Target asymmetric return 3:1 (upside 25% vs downside 8–10%).
• Options play on Stryker (SYK) — buy 9–12 month call spread (OTM) to express pricing power in OR equipment and tuck‑ins from re‑shoring. Cost‑capped exposure with 3–4x upside if innovation and pricing convert into order flow; max loss = premium paid.
• FX hedge for Baltic/Scandi exposures — enter a 6–12 month long SEK forward or buy USD/SEK put to protect translation risk for Nordic medtechs. Cost is modest vs potential 8–12% P&L swing if SEK weakens further; reduce hedge as company demonstrates >2 quarters of margin re‑capture.